Completed
Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany
What is being tested
Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
Drug
Who is being recruted
Eye Diseases
+ Glaucoma
+ Ocular Hypertension
Over 18 Years
+4 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Study Start: August 2007
Summary
Principal SponsorAlcon Research
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: August 1, 2007
Actual date on which the first participant was enrolled.The purpose of this study is to assess the safety and efficacy of transitioning uncontrolled glaucoma patients to DuoTrav from other mono or adjunctive therapies.
Official TitleSafety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany
Principal SponsorAlcon Research
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
522 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Eye DiseasesGlaucomaOcular Hypertension
Criteria
2 inclusion criteria required to participate
Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma.
Other protocol-defined inclusion criteria may apply.
2 exclusion criteria prevent from participating
Age related.
Other protocol-defined exclusion criteria may apply.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalOne drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
CompletedOne Study Center